Cimzia passes Phase III psoriasis test

UCB Group (Euronext:UCB) and Dermira Inc. (NASDAQ:DERM) said both doses of Cimzia certolizumab pegol met the co-primary endpoints of the Phase III CIMPASI-2 study to treat moderate to severe chronic plaque psoriasis.

One primary endpoint measured the proportion of patients achieving a ≥75% improvement in PASI 75 at week 16. The response rate was 82.6% for the higher dose of Cimzia, 81.4% for the lower dose and 11.6% for placebo. The other co-primary endpoint measured the proportion of patients with a two-point improvement on a Physician's Global Assessment (PGA) scale at week 16. The response rate was 71.6% for the high dose, 66.8% for the low dose and 2% for placebo. ...